Timothy L Comstock

Summary

Affiliation: Bausch and Lomb
Country: USA

Publications

  1. ncbi Loteprednol and tobramycin in combination: a review of their impact on current treatment regimens
    Timothy L Comstock
    Bausch and Lomb Incorporated, Rochester, 1400 North Goodman Street, Rochester, NY 1460, USA
    Expert Opin Pharmacother 11:843-52. 2010
  2. pmc Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery
    Timothy L Comstock
    Bausch and Lomb Inc, Rochester, NY, USA
    Clin Ophthalmol 5:177-86. 2011
  3. pmc Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate
    Timothy L Comstock
    Global Medical Affairs, Pharmaceuticals, Bausch and Lomb Inc, 1400 North Goodman Street, Rochester, NY 14609, USA
    Int J Inflam 2012:789623. 2012
  4. pmc Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
    Bruce E Silverstein
    Shasta Eye Medical Group Inc, Redding, CA
    Clin Ophthalmol 6:1987-96. 2012
  5. pmc Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
    Timothy L Comstock
    Global Medical Affairs, Pharmaceuticals, Bausch and Lomb, Inc, Rochester, NY, USA
    Clin Ophthalmol 4:215-25. 2010
  6. ncbi Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects
    Timothy L Comstock
    Global Pharmaceuticals, Bausch Lomb, Inc, Rochester, NY 14609, USA
    Paediatr Drugs 14:119-30. 2012
  7. doi Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies
    Timothy L Comstock
    Medical Affairs, Global Pharmaceutical, Bausch and Lomb, Inc, Rochester, New York 14609, USA
    Clin Drug Investig 30:675-85. 2010
  8. doi Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials
    Timothy L Comstock
    Medical Affairs, Global Pharmaceutical, Bausch and Lomb, Inc, Rochester, New York 14609, USA
    Paediatr Drugs 12:105-12. 2010
  9. ncbi Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis
    Marguerite B McDonald
    Corneal Specialist and Cataract and Refractive Surgery, Ophthalmic Consultants of Long Island, Lynbrook, NY, USA
    Ophthalmology 116:1615-1623.e1. 2009
  10. doi Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and childre
    Bruce E Silverstein
    Shasta Eye Medical Group, Inc, Redding, California, USA
    Clin Ther 33:13-26. 2011

Collaborators

Detail Information

Publications15

  1. ncbi Loteprednol and tobramycin in combination: a review of their impact on current treatment regimens
    Timothy L Comstock
    Bausch and Lomb Incorporated, Rochester, 1400 North Goodman Street, Rochester, NY 1460, USA
    Expert Opin Pharmacother 11:843-52. 2010
    ....
  2. pmc Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery
    Timothy L Comstock
    Bausch and Lomb Inc, Rochester, NY, USA
    Clin Ophthalmol 5:177-86. 2011
    ..To compare the safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% (LE ointment), a new topical ointment formulation, with vehicle for the treatment of inflammation and pain following cataract surgery...
  3. pmc Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate
    Timothy L Comstock
    Global Medical Affairs, Pharmaceuticals, Bausch and Lomb Inc, 1400 North Goodman Street, Rochester, NY 14609, USA
    Int J Inflam 2012:789623. 2012
    ..Elevations in IOP are infrequent with LE, and the absence of a C-20 ketone precludes formation of Schiff base intermediates with lens proteins, a common first step implicated in cataract formation with ketone steroids...
  4. pmc Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
    Bruce E Silverstein
    Shasta Eye Medical Group Inc, Redding, CA
    Clin Ophthalmol 6:1987-96. 2012
    ..The purpose of this study was to determine the efficacy of besifloxacin ophthalmic suspension 0.6% when used in the treatment of bacterial conjunctivitis infections due to Pseudomonas aeruginosa...
  5. pmc Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
    Timothy L Comstock
    Global Medical Affairs, Pharmaceuticals, Bausch and Lomb, Inc, Rochester, NY, USA
    Clin Ophthalmol 4:215-25. 2010
    ..In clinical trials, besifloxacin has consistently demonstrated efficacy and safety in the treatment of patients with bacterial conjunctivitis. Besifloxacin is considered safe and is well tolerated with no observed contraindications...
  6. ncbi Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects
    Timothy L Comstock
    Global Pharmaceuticals, Bausch Lomb, Inc, Rochester, NY 14609, USA
    Paediatr Drugs 14:119-30. 2012
    ..LE/T was shown to be safe in healthy volunteers and patients aged 18 years and older with minimal effect on intraocular pressure (IOP)...
  7. doi Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies
    Timothy L Comstock
    Medical Affairs, Global Pharmaceutical, Bausch and Lomb, Inc, Rochester, New York 14609, USA
    Clin Drug Investig 30:675-85. 2010
    ..Besifloxacin is a novel fluoroquinolone, specifically a chloro-fluoroquinolone, with potent broad-spectrum bactericidal activity for the topical treatment of bacterial conjunctivitis...
  8. doi Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials
    Timothy L Comstock
    Medical Affairs, Global Pharmaceutical, Bausch and Lomb, Inc, Rochester, New York 14609, USA
    Paediatr Drugs 12:105-12. 2010
    ..Besifloxacin is a new topical fluoroquinolone, the first chlorofluoroquinolone, for the treatment of bacterial conjunctivitis...
  9. ncbi Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis
    Marguerite B McDonald
    Corneal Specialist and Cataract and Refractive Surgery, Ophthalmic Consultants of Long Island, Lynbrook, NY, USA
    Ophthalmology 116:1615-1623.e1. 2009
    ..To compare the clinical and antimicrobial efficacy of besifloxacin ophthalmic suspension 0.6% with that of moxifloxacin ophthalmic solution 0.5% for the treatment of bacterial conjunctivitis...
  10. doi Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and childre
    Bruce E Silverstein
    Shasta Eye Medical Group, Inc, Redding, California, USA
    Clin Ther 33:13-26. 2011
    ..Pharmacokinetic/pharmacodynamic modeling suggests that besifloxacin might also be effective given twice daily...
  11. ncbi Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children
    Jesse DeLeon
    Center for Clinical Trials, LLC, Paramount, CA, USA
    Clin Drug Investig 32:303-17. 2012
    ..This study evaluated the safety and efficacy of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days compared with vehicle in the treatment of bacterial conjunctivitis...
  12. doi Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application
    Eric D Donnenfeld
    Ophthalmic Consultants of Long Island, Bausch and Lomb, Inc Rochester, New York, USA
    J Cataract Refract Surg 37:1082-9. 2011
    ..3%, and to assess these concentrations relative to the minimum inhibitory concentration for 90% of strains (MIC(90)) for each drug against bacterial pathogens identified in recent cases of postoperative endophthalmitis...
  13. ncbi Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans
    Joel W Proksch
    Global Research and Development, Bausch and Lomb, 1400 N Goodman Street, Rochester, NY 14609, USA
    J Ocul Pharmacol Ther 25:335-44. 2009
    ..Studies were conducted to evaluate the ocular penetration and systemic exposure to besifloxacin, a fluoroquinolone antibiotic, following topical ocular administration to animals and humans...
  14. ncbi Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis
    Eric M White
    Complete Family Vision Care, San Diego, CA, USA
    Curr Med Res Opin 24:287-96. 2008
    ..5%/tobramycin 0.3% (LE/T; Zylet) with dexamethasone 0.1%/tobramycin 0.3% (DM/T; Tobradex) in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis...
  15. pmc Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
    Timothy W Morris
    Microbiology and Sterilization Sciences, Bausch and Lomb, Rochester, NY, USA
    Clin Ophthalmol 5:1359-67. 2011
    ..6%, administered three times a day (TID) for 5 days, integrated across three clinical trials of bacterial conjunctivitis and to investigate any microbiological eradication failures...